Business Context and Reporting Period
Creative Medical Technology Holdings, Inc. filed this Form 8-K on July 2, 2019, reporting the completion of a private placement transaction on that date. The company is incorporated in Nevada and maintains its principal executive offices in Phoenix, Arizona.
Key Financial Metrics and Transaction Details
The filing details a capital raise involving two institutional investors. Key terms include:
- Total Proceeds: $100,000 ($50,000 per investor).
- Debt Instrument: 8% Original Issue Discount Senior Convertible Notes with a total principal amount of $108,000 ($54,000 per investor).
- Equity Instrument: Warrants to purchase a total of 11,111,110 shares of common stock (5,555,555 per investor).
- Interest Rate: 8% per annum.
- Maturity Date: June 27, 2020.
- Warrant Exercise Price: $0.0045 per share, exercisable for five years.
The filing does not provide specific data on the company's overall revenue, profit, cash flow, margins, or total debt levels outside of this specific transaction.
Material Changes and Terms
The primary material change is the creation of a direct financial obligation and the issuance of unregistered equity securities. Notable terms affecting future financials include:
- Conversion Price: Notes are convertible at 60% of the lowest traded price of the common stock during the 15 trading days preceding the conversion date.
- Anti-Dilution: Warrants are subject to anti-dilution adjustments in the event of future equity sales below the exercise price.
- Original Issue Discount (OID): The notes were issued at a discount, with the principal amount ($54,000) exceeding the purchase price ($50,000).
Outlook, Risks, and Contingencies
Management commentary is limited to the execution of the Securities Purchase Agreement. The transaction was effected pursuant to Section 4(a)(2) of the Securities Act and Rule 506(b). The filing incorporates by reference the full terms of the Purchase Agreement, Notes, and Warrants, which contain customary covenants and events of default. No specific forward-looking guidance or risk factors beyond the standard terms of the debt and warrant instruments are explicitly detailed in this summary text.
Investor Verification Checklist
- Verify the total number of shares outstanding post-transaction to assess the dilution impact of the 11,111,110 warrant shares.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and default triggers.
- Confirm the company's current cash position to ensure it can service the 8% interest and principal repayment due in June 2020.
- Monitor the trading price of the common stock, as the conversion price is tied to the lowest traded price over a 15-day period, which could significantly increase share count upon conversion.